ReviewFrontiers in bioengineering and biotechnology2024
MOFs for next-generation cancer therapeutics through a biophysical approach-a review.
Review in Frontiers in bioengineering and biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Engineering metal-organic framework-based smart porous nanoplatforms for targeted therapy and theranostic applications.Smart molecules : open access · 2026Review
- Metal coordination at biological interfaces: Mechanisms, therapeutics, and translation.Materials today. Bio · 2026Review
- Emerging antifungal strategies against Candida albicans using metal-organic frameworks and novel therapeutics: Opportunities and challenges.Journal of food and drug analysis · 2026Review
- A ZIF-8-modified electrochemical biosensor for sensitive Aβ aggregation monitoring and Alzheimer's disease drug screening.RSC advances · 2026Article
- γ-Cyclodextrin Metal-Organic Frameworks for Drug Delivery: Current Advances in Synthesis, Activation, Encapsulation and Applications.Pharmaceutics · 2026Review
- Tailoring Syringic Acid-Trimesic Acid Mixed-Linker MIL-100(Fe): Evaluation of Drug-Loading Capacity, Bioavailability, and Toxicity.Pharmaceutics · 2026Article
- Metal-Organic Framework-Based Drug Delivery Systems for Cancer Therapy: A Review.International journal of molecular sciences · 2026Review
- Metal-organic frameworks-mediated reactive oxygen species modulation in the tumor microenvironment of digestive system malignancies: latest advances.Frontiers in chemistry · 2026Review
- Recent advances in mitochondria-targeted porphyrin-based metal-organic frameworks for enhanced cancer therapy.Frontiers in pharmacology · 2026Review
- Progress in the Development of Metal-Organic Frameworks (MOFs) for Medical Imaging of Tumors: Prospects and Challenges.International journal of nanomedicine · 2026Review
- MIL-100(Fe)-Enabled Oral Delivery of Syringic Acid with Enhanced Pharmacokinetics.Pharmaceutics · 2025Article
- MOF enhances the sensitivity and selectivity of sorafenib as an anticancer drug against hepatocellular carcinoma and colorectal cancer in vitro.Scientific reports · 2025Article
- Recent Advancements in Metal-Organic Framework-Based Microfluidic Chips for Biomedical Applications.Micromachines · 2025Review
- Research Progress on the Structure-activity Relationship and Mechanism of Flavonoid Derivatives in the Treatment of Lung Cancer.Molecules (Basel, Switzerland) · 2025Review
- Piezoelectric Nanomaterials for Cancer Therapy: Current Research and Future Perspectives on Glioblastoma.Journal of functional biomaterials · 2025Review
- Hybrid Nanoplatforms Based on Photosensitizers and Metal/Covalent Organic Frameworks for Improved Cancer Synergistic Treatment Nano-Delivery Systems.Molecules (Basel, Switzerland) · 2025Review
- Climate friendly MOFs synthesis for drug delivery systems by integrating AI, intelligent manufacturing, and quantum solutions in industry 6.0 sustainable approach.Toxicology research · 2025Review
- Metal-organic frameworks as nanoplatforms for combination therapy in cancer treatment.Medical oncology (Northwood, London, England) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metal-organic frameworks (MOFs) have emerged as promising nanocarriers for cancer treatment due to their unique properties. Featuring high porosity, extensive surface area, chemical stability, and good biocompatibility, MOFs are ideal for efficient drug delivery, targeted therapy, and controlled release. They can be designed to target specific cellular organelles to disrupt metabolic processes in cancer cells. Additionally, functionalization with enzymes mimics their catalytic activity, enhancing photodynamic therapy and overcoming apoptosis resistance in cancer cells. The controllable and regular structure of MOFs, along with their tumor microenvironment responsiveness, make them promising nanocarriers for anticancer drugs. These carriers can effectively deliver a wide range of drugs with improved bioavailability, controlled release rate, and targeted delivery efficiency compared to alternatives. In this article, we review both experimental and computational studies focusing on the interaction between MOFs and drug, explicating the release mechanisms and stability in physiological conditions. Notably, we explore the relationship between MOF structure and its ability to damage cancer cells, elucidating why MOFs are excellent candidates for bio-applicability. By understanding the problem and exploring potential solutions, this review provides insights into the future directions for harnessing the full potential of MOFs, ultimately leading to improved therapeutic outcomes in cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.